FDA accepts PTC Therapeutics’ NDA for Sepiapterin, aiming for breakthrough in PKU treatment

FDA accepts PTC Therapeutics’ NDA for Sepiapterin, aiming for breakthrough in PKU treatment

PTC Therapeutics, Inc. has announced a significant step forward in its mission to combat phenylketonuria (PKU) by receiving FDA acceptance for the New Drug Application (NDA) of Sepiapterin. The acceptance of this NDA, supported by positive clinical trial results, brings much-needed hope to patients managing this rare metabolic disorder. The FDA’s action sets a critical […]

PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement

PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement

PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering $1.5 billion from the Evrysdi royalty stream. The terms dictate Royalty Pharma’s acquisition of additional Evrysdi royalties worth $1 billion upfront. The deal comes with provisions for future sales, where PTC could part with all its retained […]